膀胱癌化疗和放疗耐药的遗传决定因素。
Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.
作者信息
Mari Andrea, D'Andrea David, Abufaraj Mohammad, Foerster Beat, Kimura Shoji, Shariat Shahrokh F
机构信息
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
出版信息
Transl Androl Urol. 2017 Dec;6(6):1081-1089. doi: 10.21037/tau.2017.08.19.
Abstract
Bladder cancer (BCa) is burdened by high rates of chemo- and radio-resistance. We reviewed and summarized the current evidence regarding the genetic determinants of resistance in patients treated with chemotherapy and/or radiotherapy (RT) for BCa. Genetic heterogeneity may preexist to treatment arising with tumorigenesis or increasing progressively during the treatment. Several biological pathways seem to be involved in the cellular response to treatment. These pathways comprehend mechanisms leading to modify the intracellular concentration of the drug, mechanisms leading to increase the repair of DNA damage caused by the treatment, mechanisms leading to increase cell survival, despite DNA damage, acting on the signaling pathways affecting apoptosis, mechanisms promoting autophagy. In the present review, we focused on the genetic determinants of resistance affecting the aforementioned mechanisms.
摘要
膀胱癌（BCa）面临着高化疗和放疗耐药率的负担。我们回顾并总结了目前关于接受化疗和/或放疗（RT）治疗的BCa患者耐药性遗传决定因素的证据。遗传异质性可能在肿瘤发生时就已存在于治疗前，或者在治疗过程中逐渐增加。几种生物学途径似乎参与了细胞对治疗的反应。这些途径包括导致改变药物细胞内浓度的机制、导致增加对治疗引起的DNA损伤修复的机制、导致增加细胞存活的机制（尽管存在DNA损伤，作用于影响细胞凋亡的信号通路）、促进自噬的机制。在本综述中，我们重点关注影响上述机制的耐药性遗传决定因素。
相似文献
1
Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.膀胱癌化疗和放疗耐药的遗传决定因素。
Transl Androl Urol. 2017 Dec;6(6):1081-1089. doi: 10.21037/tau.2017.08.19.
2
NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression.NF-κB 信号通路在顺铂诱导的膀胱癌化疗耐药和肿瘤进展中发挥着不可替代的作用。
Int J Oncol. 2016 Jan;48(1):225-34. doi: 10.3892/ijo.2015.3256. Epub 2015 Nov 20.
3
Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.非编码RNA在结直肠癌化疗和放疗抗性中的作用
Adv Exp Med Biol. 2016;937:207-28. doi: 10.1007/978-3-319-42059-2_11.
4
Targeting urothelial carcinoma cells by combining cisplatin with a specific inhibitor of the autophagy-inducing class III PtdIns3K complex.通过将顺铂与自噬诱导性III类磷脂酰肌醇-3-激酶（PtdIns3K）复合物的特异性抑制剂联合使用来靶向尿路上皮癌细胞。
Urol Oncol. 2018 Apr;36(4):160.e1-160.e13. doi: 10.1016/j.urolonc.2017.11.021. Epub 2017 Dec 21.
5
Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.化疗和放疗耐药的分子机制及其对癌症治疗的潜在影响。
MedComm (2020). 2021 Jun 10;2(3):315-340. doi: 10.1002/mco2.55. eCollection 2021 Sep.
6
Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer.非小细胞肺癌放（化）疗中靶向DNA损伤反应
Int J Mol Sci. 2016 May 31;17(6):839. doi: 10.3390/ijms17060839.
7
Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-κB signal-dependent and signal-independent manner.水飞蓟宾以 NF-κB 信号依赖和非依赖的方式抑制膀胱癌细胞的恶性表型和化疗耐药性。
Int J Oncol. 2017 Oct;51(4):1219-1226. doi: 10.3892/ijo.2017.4089. Epub 2017 Aug 2.
8
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.顺铂耐药的多因素机制在长期治疗的尿路上皮癌细胞系中。
Int J Mol Sci. 2018 Feb 16;19(2):590. doi: 10.3390/ijms19020590.
9
EZH2 targeting to improve the sensitivity of acquired radio-resistance bladder cancer cells.靶向EZH2以提高获得性放射性抗性膀胱癌细胞的敏感性。
Transl Oncol. 2022 Feb;16:101316. doi: 10.1016/j.tranon.2021.101316. Epub 2021 Dec 21.
10
YWHAZ amplification/overexpression defines aggressive bladder cancer and contributes to chemo-/radio-resistance by suppressing caspase-mediated apoptosis.YWHAZ 扩增/过表达定义了侵袭性膀胱癌，并通过抑制半胱天冬酶介导的细胞凋亡来导致化疗/放疗耐药。
J Pathol. 2019 Aug;248(4):476-487. doi: 10.1002/path.5274. Epub 2019 Apr 29.
引用本文的文献
1
CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.含CUB结构域蛋白1信号传导失调会导致吉西他滨代谢异常，从而导致T24细胞产生治疗抗性。
PLoS One. 2025 Sep 2;20(9):e0331289. doi: 10.1371/journal.pone.0331289. eCollection 2025.
2
The Surgical Imprint: How Operative Trauma May Shape Radiation Tolerance After Prostatectomy.手术印记：前列腺切除术后手术创伤如何影响放射耐受性
Cancers (Basel). 2025 Aug 18;17(16):2685. doi: 10.3390/cancers17162685.
3
Long-term resident adipose-derived stromal stem cells in the microenvironment remodeling BLCA cell stemness and EMT promotes bladder cancer progression.长期驻留的脂肪来源基质干细胞在微环境重塑中使膀胱癌细胞干性和上皮-间质转化增强，从而促进膀胱癌进展。
Sci Rep. 2025 Jul 2;15(1):23049. doi: 10.1038/s41598-025-07387-7.
4
Progress on liposome delivery systems in the treatment of bladder cancer.脂质体递送系统在膀胱癌治疗中的研究进展
RSC Adv. 2025 May 6;15(18):14315-14336. doi: 10.1039/d5ra00746a. eCollection 2025 Apr 28.
5
Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer.热疗可降低膀胱癌的侵袭性，并对抗化疗耐药和免疫逃逸。
Int J Oncol. 2024 Dec;65(6). doi: 10.3892/ijo.2024.5704. Epub 2024 Nov 8.
6
Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms.生物信息学分析和实验验证表明，CDC20 过表达促进膀胱癌的进展和潜在的潜在机制。
Genes Genomics. 2024 Apr;46(4):437-449. doi: 10.1007/s13258-024-01505-x. Epub 2024 Mar 4.
7
Multi-omics reveals the role of ENO1 in bladder cancer and constructs an epithelial-related prognostic model to predict prognosis and efficacy.多组学揭示了ENO1在膀胱癌中的作用，并构建了一种上皮相关的预后模型来预测预后和疗效。
Sci Rep. 2024 Jan 25;14(1):2189. doi: 10.1038/s41598-024-52573-8.
8
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer.基于吉西他滨耐药细胞的 RNA 测序的代谢重编程揭示 FASN 基因是膀胱癌的一种治疗方法。
J Transl Med. 2024 Jan 13;22(1):55. doi: 10.1186/s12967-024-04867-8.
9
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).厄洛替尼联合吉西他滨和顺铂用于局部晚期或转移性胰腺癌患者的一线治疗：一项随机、开放标签的 III 期临床试验（LAP 07）
Br J Cancer. 2024 Feb;130(3):434-441. doi: 10.1038/s41416-023-02513-6. Epub 2023 Dec 15.
10
Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics.膀胱癌：治疗挑战及3D细胞培养系统在新型癌症治疗药物筛选中的作用
Cancer Cell Int. 2023 Oct 25;23(1):251. doi: 10.1186/s12935-023-03069-4.
本文引用的文献
1
HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation.高迁移率族蛋白B1（HMGB1）介导的自噬通过激活JNK和ERK减轻吉西他滨诱导的膀胱癌细胞凋亡。
Oncotarget. 2017 May 11;8(42):71642-71656. doi: 10.18632/oncotarget.17796. eCollection 2017 Sep 22.
2
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer.遗传因素对非小细胞肺癌铂类化疗敏感性和预后的影响。
Mutat Res Rev Mutat Res. 2017 Jan-Mar;771:32-58. doi: 10.1016/j.mrrev.2016.11.003. Epub 2016 Nov 23.
3
Cancer Statistics, 2017.《2017 年癌症统计》
CA Cancer J Clin. 2017 Jan;67(1):7-30. doi: 10.3322/caac.21387. Epub 2017 Jan 5.
4
Timing of DNA lesion recognition: Ubiquitin signaling in the NER pathway.DNA损伤识别的时机：核苷酸切除修复途径中的泛素信号传导
Cell Cycle. 2017 Jan 17;16(2):163-171. doi: 10.1080/15384101.2016.1261227. Epub 2016 Dec 8.
5
Genomic evolution and chemoresistance in germ-cell tumours.生殖细胞肿瘤中的基因组进化与化疗耐药性
Nature. 2016 Nov 30;540(7631):114-118. doi: 10.1038/nature20596.
6
Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery.肌肉浸润性、局部晚期和转移性膀胱尿路上皮癌的管理：一项重点关注手术作用的文献综述
Transl Androl Urol. 2016 Oct;5(5):735-744. doi: 10.21037/tau.2016.08.23.
7
Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.药物遗传学和种族对结直肠癌奥沙利铂治疗的影响：一项荟萃分析。
Pharmacogenomics. 2016 Oct;17(15):1725-1732. doi: 10.2217/pgs-2016-0102. Epub 2016 Sep 16.
8
Genomic characterization of response to chemoradiation in urothelial bladder cancer.尿路上皮膀胱癌对放化疗反应的基因组特征分析
Cancer. 2016 Dec 1;122(23):3715-3723. doi: 10.1002/cncr.30219. Epub 2016 Aug 1.
9
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.2016 年更新版 EAU 肌层浸润性和转移性膀胱癌临床实践指南。
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.
10
Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.化疗反应生物标志物ERCC2在肌层浸润性尿路上皮膀胱癌中的临床验证
JAMA Oncol. 2016 Aug 1;2(8):1094-6. doi: 10.1001/jamaoncol.2016.1056.
Zotero 插件